Female 19 years

Failed allograft (right lobe); Early graft dysfunction in both recipients of the same split liver, both requiring re-transplanting at day 8. It subsequently emerged that the donor died from thrombotic complications related to the Astra-Zeneca covid vaccine.

Female 2 years

Failed allograft (left lobe).

Female 21 years

Liver Transplant January 18 (seronegative hepatitis). 2x previous episodes cellular rejection. Unexplained fever and elevated ALT. ?further rejection.

Female 65 years

Liver transplant August 2020 for NAFLD cirrhosis. ?CMV hepatitis ?other hepatitis ?rejection.

Male 58 years

Transplanted for alcohol-related cirrhosis (DBD donor). Re-do one year later for ischaemic cholangiopathy.

Male 64 years

First biopsy late June 2021 - 'New lymphadenopathy, informal report of suspicion of lymphoma on LN biopsy [at peripheral hospital - referred to a second centre]. Previous toxoplasmosis.' Report of referred LN biopsy - post-transplant lymphoproliferative disorder (PTLD), described to show large blast-like B cells which are positive for CD30, MUM1 and EBERs in situ hybridisation. Immunophenotype on liver biopsy - scattered large B cells present in the liver biopsy, although MUM1 positive, do not express CD30 and are negative for EBERs (EBV) on in-situ hybridisation. Treated with methylprednisolone and rituximab for EBV-driven post-transplant lymphoproliferative . Disorder as first biopsy was being reported.

Male 64 years

Second liver biopsy early August 2021 - 'Lymphadenopathy improved after treatment. LFTs worsened - Bilirubin 708, ALT 184, ALP 1860.'

Male 64 years

Recurrent PSC on MRCP. Treated with increased dose of ciclosporin, methylprednisolone once off, and restarted on MMF.

Male 61 years

Liver transplant 5 months ago. ? Rejection.